O
OS Therapies Incorporated (OSTX)
ASE – Real Time Price. Currency in USD
1.62
+0.01 (0.94%)
At close: Aug 12, 2026, 3:59 PM EDT
1.60
-0.01 (-0.62%)
After-hours: Aug 12, 2026, 7:34 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
1.62
+0.01 (0.94%)
At close: Aug 12, 2026, 3:59 PM EDT
1.60
-0.01 (-0.62%)
After-hours: Aug 12, 2026, 7:34 PM EDT
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
| Name | Position |
|---|---|
| Dr. Robert G. Petit II, Ph.D. | Chief Medical Officer & Chief Scientific Officer |
| Mr. Christopher P. Acevedo | Chief Financial Officer |
| Mr. Gerald E. Commissiong | Chief Business Officer |
| Mr. Jack Doll | Chief of Staff |
| Mr. Paul A. Romness M.P.H. | Founder, Chairman, President & CEO |
| Date | Type | Document |
|---|---|---|
| 2026-07-29 | 8-K | ea0299692-8k_ostherapies.htm |
| 2026-07-24 | DEFA14A | ea0298964-defa14a_osthera.htm |
| 2026-07-24 | DEF 14A | ea0298814-01.htm |
| 2026-07-16 | D | |
| 2026-07-07 | 8-K/A | ea0297249-8ka1_ostherapies.htm |
| 2026-07-02 | 8-K | ea0296868-8k_ostherapies.htm |
| 2026-05-18 | 10-Q | ea0290259-10q_ostherap.htm |
| 2026-05-15 | NT 10-Q | ea0291171-nt10q_ostherapies.htm |
| 2026-04-30 | 8-K | ea0288588-8k_ostherapies.htm |
| 2026-04-02 | 8-K | ea0284488-8k_ostherapies.htm |